Press Releases
-
GHIT Fund Awarded Open Philanthropy Grant to Expand Funding Sources for Global Health R&D
-
Approx. USD 4.0 M Invested in Product Development for NTDs - GHIT’s First Investment in the Development of Diagnostics for Trachoma
-
Dr. Quarraisha Abdool Karim, Hideyo Noguchi Africa Prize Winner, Joins GHIT Fund Board of Directors
-
Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners including Japanese pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-based institutions
-
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
GHIT has financed the Pediatric Praziquantel Consortium’s development of arpraziquantel since 2013, investing 1.85 billion yen -
Investment of Approximately USD 8.8 Million for New Drug Development against Malaria in Partners including Marubeni and Eisai
-
GHIT Fund Welcomes EIKEN CHEMICAL as New Sponsor
-
GHIT Fund and the Medicines Patent Pool Strengthen Ties to Improve Access to Medicines
-
Global Health Innovative Technology Fund and Institut Pasteur de Dakar Announce New Partnership to Advance Research and Development for New Diagnostics and Vaccines in LMICs
-
Approximately USD 8 million Investment for New Vaccine and Drug Development against Malaria in Sumitomo Pharma, Mitsubishi Tanabe Pharma and new product development in NTDs
-
GHIT Fund Welcomes Remedy & Company Corporation as New Funding Partner
-
GHIT Fund welcomes Fujirebio as New Funding Partner
-
Global health leaders adopt the Nagasaki Outcomes Statement and jointly call for the acceleration of R&D, access, and delivery for neglected tropical diseases
-
Government of Japan Express its Pledge of US$200 Million to GHIT Fund/UNDP Replenishment
-
“Nagasaki Outcome Statement” to accelerate progress on neglected tropical diseases (NTDs) for G7 Health Ministers. “Accelerating Research and Development, and Access and Delivery for NTDs”
-
GHIT Fund Secures USD 24 million pledge from Bill & Melinda Gates Foundation over 3 years
-
A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug and Vaccine Development for Neglected Tropical Diseases
-
GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development
-
Unitaid and the Global Health Innovative Technology Fund strengthen ties to improve access to critical health tools
-
The European Medicines Agency (EMA) Validated Regulatory Application for Arpraziquantel, a potential Treatment for Schistosomiasis in Preschool-Aged Children
-
GHIT Fund Secures US$20 million pledge from Wellcome over 5 years
-
GHIT Fund Announces New Investments: A Total of 790 Million Yen for Product Development of Neglected Tropical Diseases
-
CEPI and GHIT collaborate to advance the global fight against infectious diseases
-
GHIT Fund Announces New Investments: A Total of 740 Million Yen for Malaria Drugs and Vaccine
-
GHIT Fund Announces Appointment of Dr. Osamu Kunii as New CEO
-
The Pediatric Praziquantel Consortium Announces Positive Phase III Results for Arpraziquantel To Treat Schistosomiasis
-
GHIT Fund Announces New Investments: A Total of 750 Million Yen in Drugs for Malaria and Chagas Disease, Vaccine for Malaria, and Diagnostics for Tuberculosis
-
GHIT Fund Announces New Investment: 97.4 Million Yen to Identify Novel Dual-Acting Bactericidal Drug Targets Against Mycobacterium Tuberculosis
-
GHIT Fund Announces New Investments: A Total of 960 Million Yen in Drugs for Leishmaniasis and Diagnostics for Buruli Ulcer and Chagas Disease
-
GHIT Fund Announces New Investments: A Total of 2.3 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease and Visceral Leishmaniasis, Vaccine for Malaria and Diagnostics for Tuberculosis
-
GHIT and EDCTP co-invest additional 7.8 million Euro in the Pediatric Praziquantel Consortium's access program to ensure treatment of schistosomiasis for preschool-aged children
-
GHIT Fund Announces New Investments: A Total of 230 Million Yen in Drugs for Malaria and Chagas Disease
-
GHIT Fund Announces New Investments: A Total of 1.37 Billion Yen in Drugs for Malaria, Chagas Disease, Leishmaniasis, Schistosomiasis, and Soil-Transmitted Helminths, and Diagnostics for Malaria, Buruli Ulcer, and Schistosomiasis
-
GHIT Fund Announces New Investments: A Total of 3.29 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease, Lymphatic Filariasis, and Onchocerciasis, Vaccines for Malaria, and Diagnostics for Leishmaniasis and Mycetoma
-
Statement: The Global Health Innovative Technology Fund and Unitaid collaboration to accelerate access to innovative solutions
-
GHIT Fund Announces New Investments: A Total of 630 Million Yen in Drug for Malaria, Tuberculosis, Chagas disease, and Leishmaniasis, Vaccines for Malaria and Chagas disease, and Diagnostics for Malaria
-
GHIT Fund Announces Appointment of Catherine Ohura as New CEO and Executive Director
-
GHIT Fund Announces New Investments: A Total of 2.86 Billion Yen in Drug for Schistosomiasis, Dengue, Malaria and Tuberculosis, Vaccines for Leishmaniasis and Malaria, and Diagnostics for Tuberculosis
-
GHIT Fund Announces New Investments in Vaccines for Dengue and Leishmaniasis, and Drug Screening for Malaria and Tuberculosis
-
GHIT Fund welcomes Ono Pharmaceutical Co., Ltd. as New Funding Partner
-
GHIT Fund Invests in FIND and Fujifilm for Development of Innovative Rapid Diagnostic Tool for Tuberculosis
-
GHIT Fund Names Hiroki Nakatani as Board Chair
-
As the GHIT Fund Closes Out First Five Years of R&D for Lifesaving Medical Breakthroughs, It Launches Next Phase, Focusing on Access and Delivery, Bringing Total Investment to 13.2 Billion Yen (US$123 Million)
-
GHIT Fund’s Strategic Plan for 2018 to 2022: Accelerating Product Development and Product Delivery for its global health innovations
-
EDCTP and Global Health Innovative Technology Fund partnership for the development of a paediatric formulation for schistosomiasis
-
GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma
-
GHIT Fund Secures Commitments of Over US$200 Million to its Replenishment for the Acceleration of Japanese Innovation for Infectious Diseases of the Developing World
-
GHIT Fund Invests in Late-stage Trial for Child-friendly “Snail Fever” Medicines—One of the Most Debilitating and Widespread Parasitic Diseases in Africa
-
GHIT Fund Steps Up Battle Against Neglected Diseases With Continued Investments to Move Promising Research Through the Pipeline
-
GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com
-
Government of Japan Announces Decision to Contribute US$130 million to GHIT Fund/UNDP Replenishment
-
GHIT Fund Announces New Investments, Including Innovative Malaria Vaccine Targeting Two Deadliest Strains of the Disease
-
From a Phase 2 TB Vaccine Trial, to Early Work to Neutralize Drug-Resistant Malaria, $10.7 Million in New Investments from GHIT Fund Escalates and Diversifies Japan’s Global Health Commitments
-
GHIT, Takeda and MMV progress first-in-class antimalarial DSM265 to patient trials in Peruvian Amazon
-
GHIT Fund Welcomes the Wellcome Trust and Sysmex Corporation as New Funders and ANA, Morrison & Foerster, and Yahoo! Japan as New Sponsors
-
DNDi and Four Pharmaceutical Companies Announce ‘Drug Discovery Booster’ Experiment to Accelerate and Expand Discovery of New Drugs for Two Highly Neglected Diseases – Leishmaniasis and Chagas disease
-
GHIT Fund Expands Portfolio to Nearly $43 Million with Inclusion of First Diagnostic Technology, New Drug Series for Leishmaniasis, and Four New Companies to its Screening Platform
-
New Investment in Promising Compounds for Antimalarial Drug Discovery
-
GHIT Fund Launches Target Research Platform in partnership with Grand Challenges
-
Chugai Pharmaceutical Joins GHIT Fund as Partner, Further Expanding Japanese Innovation to Target Diseases that Affects the World’s Poorest People
-
Call for greater collaboration between East and West to tackle inevitable threat of infectious diseases
-
GHIT Fund Awards $60,000 Grant Investment to Develop Innovative New Malaria Treatment
-
Seven New Grant Investments for $15.3 Million to Tackle Malaria, Chagas Disease and Dengue, which is Dramatically on the Rise
-
GHIT Certified As A Public Interest Incorporated Association
-
With a Pledge for New Funding, Global Health Innovative Technology Fund Endorses London Declaration on Neglected Tropical Diseases
-
Japanese Fund Moves Quickly to Invest in Promising Technology Against Malaria, Tuberculosis And Chagas Disease
-
Japan Launches Bold Effort to Fight Neglected Diseases by Screening Massive Drug Compound “Libraries” for New Treatments
-
Announcement of the Establishment of The Global Health Innovative Technology Fund